Recombinant Human TNFRSF18 Protein, His-tagged
Cat.No. : | TNFRSF18-370H |
Product Overview : | Recombinant human TNFRSF18, fused to His-tag at C-terminus, was expressed in insect cell and purified by using conventional chromatography techniques. |
- Specification
- Gene Information
- Related Products
- Download
Description : | TNFRSF18, also known as tumor necrosis factor receptor superfamily member 18, belongs to the tumor necrosis factor receptor superfamily. It is receptor for TNFSF18 and seems to be involved in interactions between activated T-lymphocytes and endothelial cells and in the regulation of T-cell receptor-mediated cell death. It is mediated NF-kappa-B activation via the TRAF2/NIK pathway. |
Source : | Insect cell |
Species : | Human |
Tag : | His |
Form : | Liquid. In Phosphate Buffered Saline (pH 7.4) containing 10% glycerol. |
Molecular Mass : | 15.6kDa (145aa)18-28KDa (SDS-PAGE under reducing conditions.) |
AA Sequence : | QRPTGGPGCG PGRLLLGTGT DARCCRVHTT RCCRDYPGEE CCSEWDCMCV QPEFHCGDPC CTTCRHHPCP PGQGVQSQGK FSFGFQCIDCASGTFSGGHE GHCKPWTDCT QFGFLTVFPG NKTHNAVCVP GSPPAEPLEH HHHHH |
Endotoxin : | < 1.0 EU per 1 microgram of protein (determined by LAL method) |
Purity : | >95% by SDS - PAGE |
Storage : | Can be stored at +4 centigrade short term (1-2 weeks). For long term storage, aliquot and store at -20 centigrade or -70 centigrade. Avoid repeated freezing and thawing cycles. |
Concentration : | 0.5mg/ml (determined by Absorbance at 280nm) |
Gene Name : | TNFRSF18 tumor necrosis factor receptor superfamily, member 18 [ Homo sapiens ] |
Official Symbol : | TNFRSF18 |
Synonyms : | TNFRSF18; tumor necrosis factor receptor superfamily, member 18; tumor necrosis factor receptor superfamily member 18; AITR; CD357; GITR; activation-inducible TNFR family receptor; glucocorticoid-induced TNFR-related protein; TNF receptor superfamily activation-inducible protein; GITR-D; |
Gene ID : | 8784 |
mRNA Refseq : | NM_004195 |
Protein Refseq : | NP_004186 |
MIM : | 603905 |
UniProt ID : | Q9Y5U5 |
Chromosome Location : | 1p36.3 |
Pathway : | Cytokine-cytokine receptor interaction, organism-specific biosystem; Cytokine-cytokine receptor interaction, conserved biosystem; Downstream signaling in naive CD8+ T cells, organism-specific biosystem; |
Function : | binding; receptor activity; tumor necrosis factor-activated receptor activity; |
Products Types
◆ Recombinant Protein | ||
Tnfrsf18-666R | Recombinant Rhesus macaque Tnfrsf18 Protein, Fc-tagged | +Inquiry |
TNFRSF18-2769H | Recombinant Human TNFRSF18 Protein, His-tagged | +Inquiry |
TNFRSF18-1611C | Recombinant Cynomolgus TNFRSF18 protein, His-tagged | +Inquiry |
TNFRSF18-2086H | Recombinant Human TNFRSF18 protein, hFc-tagged | +Inquiry |
TNFRSF18-329H | Recombinant Human TNFRSF18 protein, His-tagged | +Inquiry |
◆ Lysates | ||
TNFRSF18-1143HCL | Recombinant Human TNFRSF18 cell lysate | +Inquiry |
TNFRSF18-1245RCL | Recombinant Rat TNFRSF18 cell lysate | +Inquiry |
Related Gene
Not For Human Consumption!
Inquiry
- Reviews
- Q&As
Customer Reviews (3)
Write a reviewThis flexibility enables researchers like myself to tailor TNFRSF18 protein experiments to our unique needs, enhancing the reliability and relevance of the obtained results.
Their commitment to delivering exceptional products and assisting with any challenges that may arise ensures a successful and rewarding experimental journey.
The TNFRSF18 protein offered by the manufacturer is of exceptional quality, and it meets the rigorous standards necessary for my experimental needs.
Q&As (5)
Ask a questionClinical trials are investigating TNFRSF18 agonists, such as monoclonal antibodies, in combination with other cancer treatments in various cancer types.
As of my knowledge cutoff date in January 2022, there were no approved TNFRSF18-targeted therapies for cancer. However, this may have changed since then.
Side effects may include immune-related adverse events, similar to those seen with other immunotherapies, and can range from mild to severe.
TNFRSF18-targeted therapies may enhance the body's immune response against cancer cells, leading to better tumor control and improved patient outcomes.
Yes, combination therapies involving TNFRSF18 agonists and other immunotherapies are under investigation to improve treatment efficacy.
Ask a Question for All TNFRSF18 Products
Required fields are marked with *
My Review for All TNFRSF18 Products
Required fields are marked with *
Inquiry Basket